ASCO
Coverage of ASCO in the Nexus archive.
- STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
The ASCO meeting highlighted discussions on barriers to cancer care and new treatments, including Brian Wolpin's presentation on the daraxonrasib pancreatic cancer study, which received a sustained standing ovation. The article concludes with a farewell from Chicago and an invitation to a virtual recap.
- STAT+: A standing ovation for RevMed, and caution for Akeso
The article reports that RevMed received a standing ovation at the ASCO annual meeting, while Akeso faced caution. The event's plenary session concluded, but the conference continues with further sessions and a virtual recap.
- STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
BioNTech and Pfizer presented bispecifics data at the ASCO annual meeting. FDA's Pazdur highlighted a positive outlook despite challenges. The article is part of STAT+'s coverage of the event.
- STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
The article highlights positive data presented at the ASCO annual meeting for Bristol in multiple myeloma and Pfizer in lung cancer. STAT's coverage focuses on key developments from the event, emphasizing advancements in cancer treatments.
- Biotech exec Jeremy Levin on the industry’s strategic turning point
Jeremy Levin's new book 'Biotech in the Balance' addresses challenges facing the biotech industry and offers a roadmap for its future. The article also recaps recent biotech developments, including Eli Lilly's gene-editing treatment for high cholesterol and a longevity startup's funding.
- STAT+: Ahead of ASCO, all eyes on pancreatic cancer
Scientists report early progress in engineered heart patches and GSK announces a functional cure for hepatitis B. The article also highlights potential drug launches tied to President Trump's 'most-favored nation' claims and previews the upcoming ASCO meeting in Chicago.
- An ASCO preview: What to watch for at cancer research’s big meeting
The American Society of Clinical Oncology (ASCO) annual meeting is set to begin in Chicago on June 2, 2024, and run through June 2. The event is a major gathering for cancer research, with STAT producing a free pop-up newsletter covering the conference.
- STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
Merck and China-based Kelun-Biotech's drug sacituzumab tirumotecan demonstrated a 65% reduction in tumor progression risk in Phase 3 lung cancer trials. The study represents the first successful combination of an antibody-drug conjugate with PD-1 immunotherapy in advanced non-small cell lung cancer patients, with preliminary survival benefits observed.